glp-1 drug least chemical modification GLP-1-based therapies for type 2 diabetes: from single glp-1_analogs [TUSOM | Pharmwiki]

They shift with the indication, the dose a clinician selects, individual biology, and how consistently the protocol is followed

Treatment regimens followed best practice recommendations but naturally varied inter-individually, inducing potential bias

The peptide doesn't need to stay in your system to keep working because the work it does isn't dependent on its continued presence

It supports tissue healing and regeneration throughout the body, particularly in the gastrointestinal system, connective tissues, and musculoskeletal structures

Future directions will focus on precision-engineered platforms that not only eradicate biofilms and drug-resistant pathogens but also facilitate tissue regeneration, microbiome restoration, and real-time therapeutic modulation